Cell Signaling Technology

HIP2 (D27C4) Rabbit Monoclonal Antibody

#8226 · western blot · $161,351

61
Evidence Score · Well-Established
Used by 87 independent labs across 100 papers. How we score this →
100
Citing papers
16.8k
Combined citations
Supplier page Find this product

Research areas

Multiple Myeloma Research and Treatments27PI3K/AKT/mTOR signaling in cancer10Protein Degradation and Inhibitors10Ubiquitin and proteasome pathways9Immune Cell Function and Interaction7Cytokine Signaling Pathways and Interactions7Endoplasmic Reticulum Stress and Disease6Cancer therapeutics and mechanisms5

Papers citing this product

1
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Blood·2006·1.1k cit.·DOI
2
BM mesenchymal stromal cell–derived exosomes facilitate multiple myeloma progression
Journal of Clinical Investigation·2013·782 cit.·DOI
3
Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
Cancer Research·2007·671 cit.·DOI
4
Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway
Blood·2007·575 cit.·DOI
5
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu
Blood·2007·472 cit.·DOI
6
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells
Blood·2006·421 cit.·DOI
7
MLKL trafficking and accumulation at the plasma membrane control the kinetics and threshold for necroptosis
Nature Communications·2020·352 cit.·DOI
8
Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy
Nature Communications·2018·325 cit.·DOI
9
PS1 activates PI3K thus inhibiting GSK‐3 activity and tau overphosphorylation: effects of FAD mutations
The EMBO Journal·2004·287 cit.·DOI
10
MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma
Proceedings of the National Academy of Sciences·2008·251 cit.·DOI

Rate this reagent

Used this in your lab? Leave a quick rating. Reviews are anonymous and verified by academic email before they appear.

Your email is never shown publicly.